Turning Possibility Into Progress: The Rush F.A.S.T. Center for Translational Research Opens in Chicago
FAST and Rush University Medical Center opened a $5 million translational research center, a groundbreaking hub built to accelerate Angelman syndrome trials and train specialists.
Expanding the Pre-Clinical Research Landscape for Angelman Syndrome
FAST currently manages over 20 active research grants for Angelman syndrome and is expanding its infrastructure by broadening its Scientific Advisory Board and streamlining its grants management system.
FAST-Affiliated Research Program at UCLA is awarded $5.8M to advance gene therapy for Angelman syndrome.
UCLA’s Dr. Roger Hollis received a $5.8 million CIRM award to advance a stem cell gene therapy for Angelman syndrome, moving the FAST-backed program closer to a Phase 1 trial.
Introducing the Innovation Seed Grant: Supporting Early-Stage Angelman Syndrome Research
FAST launches the Innovation Seed Grant, offering $10,000–$50,000 to help researchers gather early-stage data on bold, high-risk approaches to Angelman syndrome treatment.